Journal of Cancer Clinical Trials

Department of Immunology, King Faisal Specialist Hospital and Research Centre, Alfaisal University, Saudi Arabia

Publications

• Mini Review   
  Immunotherapy of Glioblastoma: Recent Advances and Future Possibilities
  Author(s): Monther Al Alwan*
  
  Glioblastoma (GBM) stands apart as the most widely recognized, forceful type of essential harmful cerebrum growth presenting a devastatingly unfortunate guess. Regardless of forceful norm of-care in careful resection and chemoradiation with temozolomide, the middle by and large endurance of patients actually stays no longer than 15 months, because of huge growth heterogeneity, immunosuppression actuated by the cancer safe microenvironment and low mutational weight. Propels in immunotherapeutic methodologies have altered the therapy of different malignant growth types and become adroitly alluring for glioblastoma. In this survey, we give an outline of the fundamental information hidden resistant focusing on and promising immunotherapeutic procedures including CAR T cells, oncolytic infections, malignant growth immunizations, and designated spot bar inhibitors th.. Read More»
  DOI: 10.37421/2577-0535.2022.7.177.

  Abstract HTML PDF